Evidera

Evidera, a PPD business specializing in Evidence, Value, and Access

[Evidera @evideraglobal]

Donald Smith authored a white paper that defines the Pre-Approval Information Exchange (PIE) Act, compares it to the U.S. Food and Drug Administration (FDA) guidance, and outlines how implementation will support advancement of new therapies to market.

📥 https://t.co/kA4mItnA3C

[Evidera @evideraglobal]

Standing room only! 👏

Paulina Rolska-Wójcik and Jessica Griffiths, members of our value and access consulting team, presented a HEOR Theater session on the new EU HTA regulation in front of an overflow crowd at #ISPOREurope.

[Evidera @evideraglobal]

The first day of #ISPOREurope has been a huge success!

Our staff in attendance snapped this group photo as they were preparing to welcome clients to the evening reception.

Stop by and see us at booth C2-001 tomorrow!

[Evidera @evideraglobal]

We're just a few days away from #ISPOREurope! We're excited to attend this year's event with @corevitasdata, Thermo Fisher Scientific's latest acquisition that enhances our #RWD and #RWE solutions.

Meet us at booth C2-001, or schedule a chat with us. » https://t.co/XJPWgRSGzJ

[Evidera @evideraglobal]

Market approval does not guarantee commercial or clinical success. Regulatory considerations, #patientadherence and inflexible clinical workflows can hinder product uptake.

Our cutting-edge #implementationscience services can help address these barriers » https://t.co/14GWrCTzoq

[Evidera @evideraglobal]

Join our webinar on 7 November to explore the benefits and challenges of collecting #realworlddata (RWD) in continued and #earlyaccessprograms.

Register today! » https://t.co/d0CCEvwHsm

[Evidera @evideraglobal]

How will new European Union (EU) health technology assessment (#HTA) regulations commencing in 2025 impact your cell and gene therapy (CGT) submission?

We have your answers. » https://t.co/B1u6nQleop

[Evidera @evideraglobal]

Discover how #healtheconomic models play a pivotal role in product development, from early planning through analyses.

Register for this upcoming expert webinar to gain valuable insights. » https://t.co/Ltkd8id6YR

[Evidera @evideraglobal]

With OncoLocator data, insights into cancer treatments are endless.

Gaining a global understanding of standard of care. Evaluating #earlyphase assets and beyond. OncoLocator is more than data — it’s data smarter.

📈 https://t.co/FVvxNQrTje

#realworldevidence #realworlddata

[Evidera @evideraglobal]

Many #noveltherapies fail to get integrated into real-world clinical practice.

It's important to conduct a contextual analysis to understand the factors that could affect uptake, adoption and sustained use of a new therapy or health care technology. » https://t.co/14GWrCU7dY

[Evidera @evideraglobal]

Regulation (EU) 2021/2282 commences in January 2025 for #oncology and #ATMPs and will be fully implemented by 2030.

Discover how our value & access consultants can aid your European #marketaccess. » https://t.co/jKexAksIwD

[Evidera @evideraglobal]

Gain real-time understanding of cancer treatment patterns with unmatched data relevance. ➠ https://t.co/FVvxNQrTje

#realworlddata

[Evidera @evideraglobal]

Regulation (EU) 2021/2282 starts in January 2025 for #oncology and #ATMPs, with full implementation by 2030.

Learn how our value & access consultants can help you prepare for market access in Europe. » https://t.co/jKexAktgmb

[Evidera @evideraglobal]

Our iValue Suite™ helps create best-in-class value stories, global value dossiers, #HTA submissions, payer communication decks and objection handlers.

Contact us today to schedule a demo. » https://t.co/XKvU9e7ZdS

[Evidera @evideraglobal]

Donald Smith authored a white paper that defines the Pre-Approval Information Exchange (PIE) Act, compares it to the U.S. Food and Drug Administration (FDA) guidance, and outlines how implementation will support advancement of new therapies to market.

📥 https://t.co/kA4mItnA3C

[Evidera @evideraglobal]

Our experts advise using a framework to assess options for transformative medicines in order to maximize the value of #IntegratedScientificAdvice. But, that's not always easy.

Let our insights guide you. » https://t.co/RSdym0a0kL

#patientaccess #consulting #scientificadvice

[Evidera @evideraglobal]

What is driving the future of #realworldevidence?

Learn more from our blog, in which our thought leaders outline six key trends, including #realworlddata, #marketaccess, cross-industry collaboration initiatives and more. » https://t.co/OxhbZnCq08

[Thermo Fisher @thermofisher]

We’re excited to announce the completion of the acquisition of @corevitasdata. CorEvitas provides insight to the life sciences industry that improves patient care and clinical outcomes, and together we will expand our clinical research services.

[Evidera @evideraglobal]

OncoLocator™ examines geographic differences in treatment across the most prevalent cancer indications in #womenshealth.

Would you like to explore more? Contact us for a free flat file sample and demo presentation. » https://t.co/A6VQvEvqcb

#niraparib #olaraparib #bevacizumab

[Evidera @evideraglobal]

Many #noveltherapies fail to get integrated into real-world clinical practice.

It's important to conduct a contextual analysis to understand the factors that could affect uptake, adoption and sustained use of a new therapy or health care technology. » https://t.co/14GWrCTzoq